$105M raised for Senti Bio to develop CAR-NK therapies

By The Science Advisory Board staff writers

January 6, 2021 -- Leaps by Bayer, the investment arm of Bayer AG, and Senti Biosciences (Senti Bio) have announced a $105 million series B financing round to develop chimeric antigen receptor-engineered natural killer (CAR-NK) cell cancer therapies.

Senti Biosciences uses synthetic biology to engineer gene circuits that improve cell and gene therapy products. Funds will be used to apply Senti Biosciences' gene circuit platform to develop an internal therapeutic pipeline of allogeneic CAR-NK candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma.

Senti Biosciences' gene circuits are novel and proprietary combinations of DNA that enable cells to sense their environment, perform logic, and to instruct cells to produce therapeutic proteins for enhanced safety and efficacy

Proceeds from the financing round will be used to support the development of preclinical oncology programs and expanding Senti Biosciences gene circuit technology platform across different modalities and therapeutic areas. Senti Biosciences also plans to scale up clinical manufacturing.

Bayer, Atara collaborate on CAR T-cell therapies
Bayer and Atara Biotherapeutics have entered into an agreement to research, develop, manufacture, and license mesothelin-directed chimeric antigen receptor...
Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.
Specifica transfers antibody discovery platform to Bayer
Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based...
Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter